| Item | Cat. No. | Application | Isotype |
| Anti-IL4R/CD124 mAbs [Drotokibart Biosimilar] (MABL-4607) | MABL-4607 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-TNFRSF10B/CD262/DR5/TRAILR2 mAbs [Drozitumab Biosimilar] (MABL-4608) | MABL-4608 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-ERBB3/HER3 mAbs [Duligotuzumab Biosimilar] (MABL-4609) | MABL-4609 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL4R/CD124 mAbs [Dupilumab Biosimilar] (MABL-4610) | MABL-4610 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-PDL1/CD274 mAbs [Durvalumab Biosimilar] (MABL-4611) | MABL-4611 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IGF1 and IGF2 mAbs [Dusigitumab Biosimilar] (MABL-4612) | MABL-4612 | ELISA, FACS, Functional assay, in vivo binding | G2, Lambda |
| Anti-TNFSF15/TL1A/VEGI mAbs [Duvakitug Biosimilar] (MABL-4613) | MABL-4613 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
| Anti-CD19;CD3E mAbs [Duvortuxizumab Biosimilar] (MABL-4614) | MABL-4614 | ELISA, FACS, Functional assay, in vivo binding | na;na, Kappa;Lambda |
| Anti-IL12B/CLMFp40 mAbs [Ebdarokimab Biosimilar] (MABL-4615) | MABL-4615 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL13RA1/CD213A1 mAbs [Eblasakimab Biosimilar] (MABL-4616) | MABL-4616 | ELISA, FACS, Functional assay, in vivo binding | G4, Kappa |
| Anti-CCL17/ABCD-2/SCYA17/TARC mAbs [Denrakibart Biosimilar] (MABL-4585) | MABL-4585 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-EGFR/ERBB1/HER1 mAbs [Depatuxizumab Biosimilar] (MABL-4586) | MABL-4586 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-IL5 mAbs [Depemokimab Biosimilar] (MABL-4587) | MABL-4587 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-DNA/H1 Complex mAbs [Derlotuximab Biosimilar] (MABL-4588) | MABL-4588 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-Metamphetamine mAbs [Devextinetug Biosimilar] (MABL-4589) | MABL-4589 | ELISA, FACS, Functional assay, in vivo binding | G2, Kappa |
| Anti-APCS/SAP mAbs [Dezamizumab Biosimilar] (MABL-4590) | MABL-4590 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-KLRD1/CD94 mAbs [Dibotatug Biosimilar] (MABL-4591) | MABL-4591 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-DLL4;VEGFA mAbs [Dilpacimab Biosimilar] (MABL-4592) | MABL-4592 | ELISA, FACS, Functional assay, in vivo binding | G1;G1, Kappa;Kappa |
| Anti-Ganglioside GD2 mAbs [Dinutuximab Biosimilar] (MABL-4593) | MABL-4593 | ELISA, FACS, Functional assay, in vivo binding | G1, Kappa |
| Anti-Influenza A HA2 mAbs [Diridavumab Biosimilar] (MABL-4594) | MABL-4594 | ELISA, FACS, Functional assay, in vivo binding | G1, Lambda |
联系我们
Copyright © 2012-2029 西安迈博睿(Mabioway)生物科技有限公司 版权所有
地址:陕西省西安市浐灞生态区广运潭大道南段4555号长安大学科技园4号楼A单元2层
电话:15339069646 邮箱:info@mabioway.cn
